This outcome was also observed when combining this drug with anti-PD-1 antibody, suggesting that the effect of NextA could operate independently of the immune checkpoint blockade, and potentially prepare the tumor microenvironment in ways that further enhance the effect of anti-PD-1 blockade treatment. Here, PDCD1 is linked to neoplasm.